Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.
Topic summary
Why the cheapest option is often not the cheapest
This is a generated summary. It shows the 5 most-liked posts from a topic of 24, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
I read post #5 twice before replying, because I had assumed the opposite.
International pricing: the same compound costs very different amounts in different countries because healthcare systems and regulatory frameworks differ. Generally, US prices are higher than other developed nations.
16 likes 2mo
v.okonkwo, post #3: Coming back to the opening post, because the follow-up matters more than the original answer. List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially. List price is not what anyone pays. Go to post
Worth separating two things that post #8 runs together.
Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be compared on price per milligram alone because dead volume, wastage, and number of doses actually obtainable differ.
f.espinoza, post #14: International pricing: the same compound costs very different amounts in different countries because healthcare systems and regulatory frameworks differ. Generally, US prices are higher than other developed nations. Go to post
Compute cost per delivered dose at your dose if you want a number you can act on. That requires knowing your dose, vial volume, and whether you are using a vial or a pen.
y.mensah, post #21: On post #17 — agreed on the reasoning, with one qualification. Discount programmes and coupons: manufacturers often offer coupons that reduce out-of-pocket costs if insurance is not covering or is covering at a high copay. These have eligibility restrictions but can save money. Go to post
Biosimilars and future generics: as patents expire, biosimilar and generic versions might become available and prices might fall. That has already happened for some proteins; incretin agonist pricing might follow.
Read the full topic (24 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
|
+24 | 28 | 50k | 12mo |
|
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+4 | 8 | 658 | 14mo |
|
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this…
|
+21 | 25 | 55k | 13mo |
|
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires.…
|
+99 | 115 | 11k | 3mo |
Related topics — sharing the tags compounding, formulary, cost per milligram
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Theoretical plates: useful number or ritual?
Asking directly, because I could not find a straight answer: Revisiting: Theoretical plates: useful number or ritual? I would like to understand what this number means before I repeat it anywhere. A…
|
+16 | 21 | 1.2k | 1d |
|
Ultrasound and skinfolds: operator dependence in practice — what changed since
Posting this under the heading it deserves: Ultrasound and skinfolds: operator dependence in practice — what changed since Everything below is what sits behind that. Longitudinal report with the method…
|
+32 | 37 | 7.4k | 3mo |
|
Deamidation and the close-eluting pair it produces — the long version
Posting this under the heading it deserves: Deamidation and the close-eluting pair it produces — the long version Everything below is what sits behind that. I would like to understand what this number means…
|
3 | 347 | 24d | |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+72 | 78 | 23k | 3mo |
|
Shoulders, tangent skims, and defensible integration — the long version
Shoulders, tangent skims, and defensible integration — the long version Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the…
|
+16 | 20 | 27k | 3mo |